Eribulin for heavily pre-treated metastatic breast cancer patients

doi:10.5493/wjem.v5.i3.194

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6846)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

334

WORD

250

HTML

2853

Figures (1-2)

168

Tables (1-3)

182

Sum=3787

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1054

Download

2005

Sum=3059

Aug 20, 2015 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Exp Med. Aug 20, 2015; 5(3): 194-199
Published online Aug 20, 2015. doi: 10.5493/wjem.v5.i3.194

Full Size Figure Download Figure

Figure 1 Kaplan-Meier Progression-Free Survival curve of the patients in this series. The Y axis depicts the percentage of patients alive without disease progression and the X axis represents months from the start of eribulin treatment. PFS: Progression-Free Survival.

Citation: Digklia A, Voutsadakis IA. Eribulin for heavily pre-treated metastatic breast cancer patients. World J Exp Med 2015; 5(3): 194-199
URL: https://www.wjgnet.com/2220-315X/full/v5/i3/194.htm
DOI: https://dx.doi.org/10.5493/wjem.v5.i3.194